Synodos for Schwannomatosis, an international consortium of clinicians and scientists from multiple disciplines, was launched at a full team meeting in Toronto, Canada on May 1, 2017. At the conclusion of this inaugural meeting, we met with the leaders of this exciting new consortium, who spoke candidly about the meeting, schwannomatosis research, and what is at stake for this important project.
Your ongoing support has allowed us to take huge steps forward in 2016 in the fight against NF. Your efforts and contributions have been instrumental in advancing neurofibromatosis research, providing hope for the millions worldwide who live with NF, and bringing us ever closer to our shared goal of ending NF forever.
Last year, the Children's Tumor Foundation announced Synodos for NF1, a unique consortium bringing together a multidisciplinary team of scientists, clinicians, technicians, patients and other experts from world-class labs at academic and medical centers. These scientists have pledged to work together and share unpublished information, datasets, and results, thereby accelerating the drug development process.
A valuable collaborator on the Synodos for NF2 consortium, Dr. Vijaya Ramesh’s work was recently showcased on the Congressionally Directed Medical Research Programs (CDMRP) homepage.
SYNODOS FOR SCHWANNOMATOSIS: REQUEST FOR APPLICATIONS
New York, NY, May 4, 2016. The Children’s Tumor Foundation is proud to launch a new consortium for schwannomatosis, the rarest and least studied form of neurofibromatosis. Based on the Synodos model for NF1 and NF2, the ‘Synodos for Schwannomatosis’ is a multi-tiered project that will bring together basic, translational, and clinical researchers towards the end goal of developing effective treatments for schwannomatosis.